ONCT
|Oncternal Therapeutics Inc
NASDAQ
USD
|%
Current Price
Change
(%)
P/E Ratio
Dividend Yield
Market Cap
1.56M
Volume
Open
Previous Close
52-Week High
USD 8.99
52-Week Low
USD 0.53
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developin...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. James B. Breitmeyer M.D., Ph.D.
Employees:27
Headquarters:San Diego, USA
Website:www.oncternal.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions